Radiance Biopharma
February 10, 2025
Oncology
Radiance is developing next generation Antibody Drug Conjugates and Bispecific ADCs. The Company's lead asset , RB164, an ROR1 ADC, is clinic ready. RB201, is a HER2/TROP2 BsADC, with next generation linker payload.
)
){kind=logo}
)
)
)
){kind=logo}
)
){kind=logo}
){kind=logo}
){kind=logo}